TORONTO, Jan. 24 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) and the
Health Care Division of ALQAEM International (FZE) ("ALQAEM") are
presenting Biosign's UFIT(R) TEN-20 at the 35th Annual Arab Health
Exhibition & Congress at the Dubai World Trade Centre, United Arab
Emirates, during January 24-27, 2011.
"The M.E.N.A. region is experiencing the fastest per capita growth in
hypertension and type-2 diabetes", stated Peter Tassiopoulos, CEO of
Biosign Technologies. "Governments, hospitals, and clinicians in the
region are focused on reducing the incidence of these serious
conditions. We intend to establish a leading position in that
multi-billion dollar market."
UFIT(R) TEN-20 is Biosign's online monitor for blood pressure and blood
glucose. The device takes the pulse at the wrist through an inflatable
cuff and immediately produces blood pressure and blood glucose
measurement results. All measurements are non-invasive and passive. The
results are stored on Biosign's servers along with the test sample. The
readings and the reports can be reviewed on a secure web portal and
integrated into electronic medical records. The system has been
assessed and certified as meeting the requirements of ISO 9001:2008,
ISO 13485-2003, and Directive 93/42/EEC ("CE Mark").
Mr. John Rizvi, Managing Director of ALQAEM, stated: "Each year, over
66,000 professionals, from 145 countries, attend this Congress. We are
excited to work directly with Biosign at such an important event and we
look forward to introducing the UFIT(R) product line to customers,
resellers, and medical professionals from the M.E.N.A. region."
Biosign and ALQAEM will be exhibiting at booth S1G61 during the
Congress. The Arab Health Exhibition & Congress is the largest
healthcare exhibition in the Middle East and the second largest
healthcare event of this type in the world (please visit
www.arabhealthonline.com). Established in 1975, it provides a platform
for the world's leading manufacturers, wholesalers, and distributors to
meet the medical and scientific community in the Middle East. The
Middle East market for healthcare products and services is
approximately $80 billion per year.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT(R) medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
About ALQAEM International (FZE)
ALQEAM is a diversified trading and distribution company headquartered
in Sharjah, United Arab Emirates. A large potion of ALQAEM's business
is healthcare focused and the company has supplied a number of
high-tech product lines to hospitals in Dubai, Abu Dhabi and the other
United Arab Emirates. In addition, ALQAEM directs healthcare sales
teams in a number of Gulf countries. In July 2010, ALQAEM was appointed
the exclusive Master Distributor for Biosign health monitoring products
for 10 countries in the M.E.N.A region. For more information, please
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information: